Multiple Myeloma: Improved Prognosis With the Latest Treatments
WEBAug 16, 2023 · Multiple myeloma is not currently curable but can be effectively managed for years. New drugs developed over the past two decades have significantly improved prognosis. Three bispecific antibodies, a form of off-the-shelf immunotherapy, have been recently approved by the FDA. Back to top.
Advances in multiple myeloma treatment - Mayo Clinic …
WEBMay 16, 2024 · Right now, there is no cure for the disease. But as Dr. Joselle Cook, a Mayo Clinic hematologist, explains, recent advances in treatment are helping people live longer. And as multiple myeloma research continues, a cure may someday be on the horizon.
Daratumumab Plus Standard Therapy for Multiple Myeloma
WEBJan 19, 2024 · A large randomized clinical trial for people newly diagnosed with multiple myeloma has found that adding the drug daratumumab (Darzalex) to a standard treatment regimen was more effective than that standard regimen on its own.
Multiple myeloma: New, better treatments are improving outcomes
WEBApr 27, 2022 · Cancer experts have been exploring and improving multiple myeloma treatments that can extend periods of remission and enhance quality of life.
How the largest-ever myeloma trial paved the way for a brighter …
WEB3 days ago · As it is the largest-ever myeloma study, it has provided a critical foundation and dataset on which other trials have been developed and built – advancing more trials and treatments for patients worldwide. A huge study like Myeloma XI is dependent on great teamwork between doctors, nurses, the pharmaceutical industry and universities across ...
FDA Approves Two New Treatments for Heavily Pretreated Multiple Myeloma
WEBRye Brook, N.Y., August 16, 2023 – The U.S. Food and Drug Administration (FDA) in August approved both talquetamab-tgvs (Talvey™) and elranatamab (Elrexfio™) to treat adults with multiple myeloma that has failed to respond or …
FDA Approves First Cell-Based Gene Therapy for Adult Patients …
WEBMar 27, 2021 · The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose...
FDA Approves Teclistamab, a Promising New Drug for Multiple Myeloma ...
WEBOct 25, 2022 · People with multiple myeloma, a rare blood cancer, got good news today when the FDA approved a new drug for resistant forms of the disease. The drug, teclistamab, has been proven effective in treating people with multiple myeloma for whom previous therapies have not worked.
FDA Approves Carvykti CAR T-Cell Therapy for Multiple Myeloma
WEBMar 30, 2022 · On February 28, the Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti) for adults with multiple myeloma that is not responding to treatment (refractory) or has returned after treatment (relapsed).
CAR T-Cell Therapy Approved for Multiple Myeloma - NCI
WEBApr 14, 2021 · A type of immunotherapy called CAR T-cell therapy is now an option for some people with multiple myeloma. On March 26, the Food and Drug Administration (FDA) approved idecabtagene vicleucel (Abecma) for people with multiple myeloma that has not responded to or has returned after at least four different prior cancer treatments.